BioSpace News Archive

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the peer-reviewed publication of a preclinical study in the journal Stem Cell and Research Therapy.

Tampa General is one of the first sites in the nation to study the safety and efficacy of the device, which aims to use focused ultrasound to destroy tumors in the liver

- Transaction to immediately accelerate clinical development of TR009 in Greater China and combine with Elpiscience’s deep pipeline of next generation immunotherapies - TRIGR and Elpiscience intend to harmonize future clinical development globally across multiple DLL4 overexpressed solid tumors

MobileODT , a FemTech company producing the latest digital innovation in cervical screening, has been awarded a prestigious Small Business Innovation Research Authority grant of $2.3 million . This grant is presented by the United States National Cancer Institute (NCI) to leading companies that are technologically and clinicall

Celularity Inc., a clinical stage cell therapeutics company focused on the development of innovative allogeneic placenta-derived cellular therapies, today announced that Robert J. Hariri , M.D., Ph.D., Founder, Chairperson and Chief Executive Officer of Celularity and members of the management team will be participating in a f

Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence (“A.I.”) platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced the closing of its previously announced public offering of 4,928,571 sha

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

QIAGEN Confirms Effectiveness of Its SARS-CoV-2 PCR Tests in the Face of Mutations of the Coronavirus QIAstat-Dx and NeuMoDx tests continue to detect all known viral variants extremely effectively

OncoSec Medical Incorporated, a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Thetis Pharmaceuticals (“Thetis”), a biopharmaceutical company developing novel therapies for autoimmune and inflammatory disorders, announced today that it completed a Pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration for its lead candidate, TP-317, a Resolvin E1 oral, small molecule therapy being developed for inflammatory bowel disease (IBD).